Mondaca S, et al. - Researchers performed the study to test the safety as well as the effectiveness of modified docetaxel, cisplatin and 5 fluorouracil (mDCF) plus trastuzumab in untreated patients with HER2-positive metastatic gastric or GE junction adenocarcinoma in this single-arm multicenter phase II trial. For this investigation, 26 of these patients were treated with mDCF and trastuzumab every 2 weeks. Neutropenia, fatigue, and hypophosphatemia were the grade 3/4 toxicities seen, with no episodes of febrile neutropenia. The 6-month PFS was 73% after a median follow-up of 25.4 months. The median PFS was 13 months and the median OS was 24.9 months. In patients with metastatic HER2-positive gastric or GE junction adenocarcinoma, the combination of mDCF and trastuzumab was effective and safe and can be considered as an option for selected patients.